NOTICES

Week of September 6, 2017

- Notice to Update Research Objectives and to Announce Continued Funding for PAS-16-033 “Stimulating Hematology Investigation: New Endeavors (SHINE) (R01)"
  (NOT-DK-17-016)
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Heart, Lung, and Blood Institute
  National Institute on Aging

- Clarification of RFA-HD-18-009 “Global Network for Women’s and Children’s Health Research (UG1)
  (NOT-HD-17-017)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

- Notice of NHLBI’s Participation on PAR-17-450 “Limited Competition: Lasker Clinical Research Scholars Transition Award (R00)"
  (NOT-HL-17-535)
  National Heart, Lung, and Blood Institute

- Notice to Allow Additional Travel Funds for DAP Participants in: Initiative to Maximize Research Education in Genomics: Diversity Action Plan (R25)
  (NOT-HG-17-013)
  National Human Genome Research Institute

- Request for Information on Bioethics Issues in Cancer Research and Care
  (NOT-CA-17-079)
  National Cancer Institute

- Notice of NCI’s participation on PAR-17-257 “Limited Competition: Lasker Clinical Research Scholars Transition Award (R00)"
  (NOT-CA-17-080)
  National Cancer Institute

- Notice of Correction in Expiration Date for PAR-17-438 “Assay development and screening for discovery of chemical probes or therapeutic agents (R01)"
  (NOT-CA-17-077)
  National Cancer Institute

- Notice of Correction in Expiration Date for PAR-17-331 “Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)"
  (NOT-CA-17-075)
  National Cancer Institute

- Notice of Correction in Expiration Date for PA-17-330 “Using Small Molecules and Molecular Genetics to Identify Novel Targets and Mechanisms Contributing to Tumor Immune Evasion (R01)"
  (NOT-CA-17-076)
  National Cancer Institute

- Notice of Correction to Activity Code in PA-17-460 “Biology of Lung, and Head and Neck Preneoplasias (R21- Clinical Trial Not Allowed)"
  (NOT-CA-17-078)
  National Cancer Institute

- Notice of NCI’s participation on PA-17-462 “Symptoms Cluster Characterization in Chronic Conditions (R01)"
  (NOT-CA-17-083)
  National Cancer Institute

- Notice of NCI’s participation on PA-17-461 “Symptoms Cluster Characterization in Chronic Conditions (R21)"
  (NOT-CA-17-082)
  National Cancer Institute

REQUEST FOR APPLICATIONS

- TITLE: Limited Competition: A Data Resource for Analyzing Blood and Marrow Transplants (U24)
  (RFA-CA-17-031)
  SPONSOR: National Cancer Institute, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases
  Synopsis: The purpose of this limited competition Funding Opportunity Announcement (FOA) is to solicit a renewal application from the Center for International Blood and Marrow Transplant Research (CIBMTR) for the continued support of the Data Resource for Analyzing Blood and Marrow Transplants program, currently funded by a cooperative agreement resource (U24) award. The support for this FOA is to ensure the continued availability of the CIBMTR database as a resource to investigators, transplant physicians, and healthcare policy-makers.
  Application Receipt Date(s): October 26, 2017

- TITLE: Metabolomics Core for the Undiagnosed Diseases Network (UDN) Phase II (U01)
  (RFA-RM-17-015)
  SPONSOR: National Institutes of Health (NIH)
  Synopsis: The purpose of this initiative is to establish an Academic-Industrial Partnership Program to develop new
and/or validate existing technologies, methods, and assays for the capture and quantification of tumor associated
cells, DNA, RNA, or exosomes in body fluids of patients with early stage disease or those at high risk; as well as
distinguishing cancer from benign disease; or aggressive from indolent cancers. The precompetitive alliances with
industry will harmonize and validate technologies, methods and assays associated with liquid biopsies.

**TITLE: Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment (U01)**
(RFA-CA-17-029)
**SPONSOR:** National Cancer Institute

**Synopsis:** The purpose of this funding opportunity announcement (FOA) is to provide the Metabolomics Core for
participants seen through the Undiagnosed Diseases Network (UDN). The Metabolomics Core will provide clinical
expertise and consultation to the UDN network. It will also provide specific expertise in the areas of glycomics,
lipidomics, and mitochondrial. The core will also serve as a network conduit **that will provide access to resources and
world class investigators with expertise in metabolomics beyond the scope of the cores’ own expertise.**

Application Receipt Date(s): November 2, 2017

**TITLE: Collaborative Research Network for Fusion Oncoproteins in Childhood Cancers (U54)**
(RFA-CA-17-049)
**SPONSOR:** National Cancer Institute

**Synopsis:** The overall goal of this funding opportunity announcement (FOA) is to establish a consortium of
collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion
oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches.
Increased attention to this important but understudied field can help overcome existing barriers to progress and pave
the way to novel therapeutic approaches with increased efficacy and fewer side effects than current options.

Application Receipt Date(s): October 24, 2017 and January 23, 2018

**TITLE: Cardiovascular and Pulmonary Research on E-Cigarettes (R01)**
(RFA-CA-17-041)
**SPONSOR:** National Cancer Institute, National Heart, Lung, and Blood Institute

**Synopsis:** The purpose of this funding opportunity announcement (FOA) is to stimulate research on cardiovascular
and pulmonary physiologic and health effects of electronic cigarette (e-cigarette) exposure. This FOA invites
applications addressing the effects of e-cigarettes on the cardiovascular and pulmonary systems, alone or in
combination. Studies involving clinical populations, animal models and/or cell preparations would all be considered
responsive.

Application Receipt Date(s): January 16, 2018

**TITLE: Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01)**
(RFA-CA-17-041)
**SPONSOR:** National Cancer Institute

**Synopsis:** This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer
MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case
ascertainment and optimize the delivery of evidence-based healthcare for individuals at high risk of cancer due to an
inherited genetic susceptibility.

Application Receipt Date(s): January 9, 2018

**PROGRAM ANNOUNCEMENTS**

(RPAR-17-473)
**SPONSOR:** Office of Disease Prevention
National Cancer Institute
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute on Minority Health and Health Disparities

Application Receipt/Submission Date(s): November 27, 2017

**TITLE: Administrative Supplements for validation studies of analytical methods for dietary supplements and natural products
(Admin. Suppl.)**
(RPAR-17-447)
**SPONSOR:** Office of Dietary Supplements
National Cancer Institute
National Center for Complementary and Integrative Health
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences
Application Receipt/Submission Date(s): October 15, 2017

- **TITLE:** Ethical, Legal, and Social Implications (ELSI) of Genomics Small Research Grant Program (R03) (PAR-17-445)
  **SPONSOR:** National Human Genome Research Institute
  Application Receipt/Submission Date(s): Standard dates apply

- **TITLE:** The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R01) (PAR-17-440)
  **SPONSOR:** National Cancer Institute
  Application Receipt/Submission Date(s): Standard dates apply

- **TITLE:** The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21) (PAR-17-449)
  **SPONSOR:** National Cancer Institute
  Application Receipt/Submission Date(s): Standard dates apply

- **TITLE:** Assay development and screening for discovery of chemical probes or therapeutic agents (R01) (PA-17-438)
  **SPONSOR:** National Cancer Institute
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  Application Receipt/Submission Date(s): Standard Dates apply

- **TITLE:** Biology of Lung, and Head and Neck Preneoplasias (R01) (PA-17-459)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.
  Application Receipt Date(s): Standard dates apply

- **TITLE:** Biology of Lung, and Head and Neck Preneoplasias (R21) (PA-17-460)
  **SPONSOR:** National Cancer Institute
  Application Receipt/Submission Date(s): Standard dates apply

- **TITLE:** Population Assessment of Tobacco and Health (PATH) Biospecimen Access (X01) (PAR-17-458)
  **SPONSOR:** National Institute on Drug Abuse
  **Synopsis:** This Funding Opportunity Announcement (FOA) allows investigators to apply for access to the Population Assessment of Tobacco and Health (PATH) Study biospecimens for use in conducting tobacco-related research and studies. The PATH Study is a collaboration between the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), and the Center for Tobacco Products (CTP), U.S. Food and Drug Administration (FDA). The PATH Study is an ongoing longitudinal cohort study on tobacco use behavior, attitudes and beliefs, and tobacco-related health outcomes.
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Symptom Cluster Characterization in Chronic Conditions (R01) (PA-17-462)
  **SPONSOR:** National Institute of Nursing Research (NINR)

- **TITLE:** Limited Competition: Lasker Clinical Research Scholars Transition Award (R00) (PAR-17-450)
  **SPONSOR:** National Cancer Institute
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute on Environmental Health Sciences
  National Institute on Nursing Research
  Application Receipt/Submission Date(s): Multiple dates, see announcement
• **TITLE:** Breast Cancer Research Program (BCRP) – Innovator Award  
  *(W81XWH-17-BCRP-INNOV2)*  
  **SPONSOR:** United States Department of Defense (DOD)

• **TITLE:** Breast Cancer Research Program (BCRP) – Distinguished Investigator Award  
  *(W81XWH-17-BCRP-DIA)*  
  **SPONSOR:** United States Department of Defense (DOD)

• **TITLE:** Independent Grants for Learning & Change (IGL&C): The Evolving Standard of Care for Patients with HR+, HER2-Breast Cancer  
  **SPONSOR:** Pfizer, Inc.

• **TITLE:** Lung Cancer Discovery Award  
  [https://pivot.cos.com/funding_opps/99874](https://pivot.cos.com/funding_opps/99874)  
  **SPONSOR:** American Lung Association (ALA)

• **TITLE:** Melanoma Research Scholar Program  
  [https://outrunthesun.org/research/2017-national-research-scholar-program/](https://outrunthesun.org/research/2017-national-research-scholar-program/)  
  **SPONSOR:** Outrun the Sun

• **TITLE:** Interventional Oncology/Immuno-Oncology Research Grant/ SIO Research Grant  
  **SPONSOR:** Society of Interventional Oncology (SIO)

• **TITLE:** Milstein Research Scholar Awards for Melanoma/Non-Melanoma Skin Cancer  
  **SPONSOR:** American Skin Association (ASA)

• **TITLE:** Collaborative Pediatric Cancer Research Awards Program: Grant Funding Opportunity in Pediatric Oncology-Independent Investigator and Consortium Grant  
  [https://rallyfoundation.org/research/become-a-rally-funded-researcher/](https://rallyfoundation.org/research/become-a-rally-funded-researcher/)  
  **SPONSOR:** Rally Foundation for Childhood Cancer Research

• **TITLE:** Advanced Clinical Research Award (ACRA)  
  [https://www.conquer.org/advanced-clinical-research-award](https://www.conquer.org/advanced-clinical-research-award)  
  **SPONSOR:** American Society of Clinical Oncology (ASCO)

• **TITLE:** Request for Proposals: Awards for Established Investigators- Pilot Awards  
  [https://www.conquer.org/advanced-clinical-research-award](https://www.conquer.org/advanced-clinical-research-award)  
  **SPONSOR:** Melanoma Research Alliance (MRA)